Neuropathic Pain: Global Market & Forecast Analysis to 2026 - The Opioid Class is Set to Succeed Anticonvulsants as Market Leader, as Lyrica Faces Generic Competition in All Markets - ResearchAndMarkets.com

DUBLIN--()--The "Neuropathic Pain Market and Forecast Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.

Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain. Neuropathic pain is not a single disease, but a syndrome caused by an array of different diseases and lesions, with common subtypes such as diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.

Market Snapshot

  • The opioid class is set to succeed anticonvulsants as market leader, as Lyrica faces generic competition in all markets.
  • Treatment of neuropathic pain has remained stagnant over recent years due to lack of innovation within the pain market.
  • The burden of neuropathic pain is difficult to estimate, but is likely high across all analyzed countries.
  • Lyrica continues to dominate neuropathic pain; however, revenues are set to fall dramatically following patent expiries.
  • Donaperminogene seltoplasmid is the only late-stage therapy to target the underlying cause of pain rather than symptoms.

Key Topics Covered

FORECAST: NEUROPATHIC PAIN (Published on 31 May 2018)

Overview

Market Dynamics

Forecast And Future Trends

Market Definition And Methodology

Primary Research Methodology

Bibliography

Product Profile: Cymbalta

Product Profile: Gralise

Product Profile: Lidoderm

Product Profile: Lyrica

Product Profile: Nucynta Er

Product Profile (Late Stage): Cebranopadol

Product Profile (Late Stage): Donaperminogene Seltoplasmid

Product Profile (Late Stage): Mirogabalin

Product Profile (Late Stage): Raxatrigine

TREATMENT: NEUROPATHIC PAIN (Published on 13 March 2018)

Overview

Executive Summary

Primary Research Methodology

Disease Definition And Diagnosis

Patient Segmentation

Current Treatment Options

Prescribing Trends

Unmet Needs In Neuropathic Pain

EPIDEMIOLOGY: NEUROPATHIC PAIN (Published on 23 October 2018)

Overview

Disease Background

Methodology

Forecast

Bibliography

MARKETED DRUGS: NEUROPATHIC PAIN (Published on 31 May 2018)

Overview

Product Overview

Product Profile: Cymbalta

Product Profile: Gralise

Product Profile: Lidoderm

Product Profile: Lyrica

Product Profile: Nucynta Er

PIPELINE: NEUROPATHIC PAIN (Published on 31 May 2018)

Overview

Clinical Pipeline Overview

Additional Pharma Intelligence Pipeline Resources

Product Profile (Late Stage): Cebranopadol

Product Profile (Late Stage): Donaperminogene Seltoplasmid

Product Profile (Late Stage): Mirogabalin

Product Profile (Late Stage): Raxatrigine

For more information about this report visit https://www.researchandmarkets.com/r/shuyl

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs, Analgesics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs, Analgesics